Although the vast majority of drug treatments target m6A regulatory genes or proteins, we found that targeting the m1A methyltransferase complex TRMT6/TRMT61A in HCC with Hiram can effectively inhibit the progression of HCC (32), indicating that targeting other RNA modification regulatory genes or proteins also has therapeutic significance. This evidence concerns the gene TRMT6 and hepatocellular carcinoma.